Delivery Order SPE2DB24D3014-SPE2DB26FKRTT
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,664.71 to AmerisourceBergen Drug Corp for Ondansetron ODT 4 mg tablets (30-count packages) on July 14, 2025, with an ultimate completion date of July 15, 2025. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. Ondansetron is a widely used anti-nausea medication commonly...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 21, 2024, for the supply of Ondansetron ODT 8 mg tablets (30 count) with a contract value of $17,810.92. This firm fixed-price delivery order, with an ultimate completion date of October 22, 2024, represents a non-competitive set-aside award supporting federal medical procurement needs. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency awarded a $8,059.34 delivery order to AmerisourceBergen Drug Corp on May 16, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30. The award is non-competitive and structured as a firm fixed price delivery order, with an ultimate completion date of May 19, 2025. Performance of this contract will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $17,306.77 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Ondansetron ODT 4 mg tablets (30-count packaging), with an ultimate completion date of September 5, 2025. This competitive award, issued on September 4, 2025, carries no set-aside designation and represents a single delivery order fulfilling pharmaceutical supply needs for federal medical procurement. The place of performance is listed as AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a delivery order valued at $4,566.42 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT (orally disintegrating tablet) 8 mg in quantities of 30 tablets. The contract is a firm fixed price delivery order with an ultimate completion date of September 19, 2025, and was awarded on September 18, 2025. This award carries no set-aside designation, indicating it was competitively awarded. The pharmaceutical product will be delivered to the Conshohocken,...
- The Defense Logistics Agency awarded a $13,399.76 delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under open competition. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of September 15, 2025. Ondansetron is an antiemetic...
- The Defense Logistics Agency awarded a delivery order valued at $8,736.12 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 MG tablets in quantities of 30 units. This competitive award, issued on July 21, 2025, with an ultimate completion date of July 22, 2025, represents a firm fixed-price delivery order with no set-aside designation. The product will be delivered to Conshohocken, Pennsylvania, the location of AmerisourceBergen's corporate headquarters. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30, with a contract ceiling value of $1,961.44. This firm fixed price delivery order is non-competitive and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical valued at $999.99 billion through December 2026. The work will be performed at...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $28,456.56 on August 15, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30. The contract employs firm fixed pricing and carries an ultimate completion date of August 18, 2025. This delivery order is issued without a set-aside designation, indicating it was competitively awarded. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Ondansetron ODT 8 mg tablets (30-count units) with a ceiling value of $4,831.51. The order, issued on September 22, 2025, with an ultimate completion date of September 23, 2025, utilizes firm fixed-price pricing under a non-set-aside competitive procurement. Performance will take place at the awardee's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- SPE2DB24D3014Indefinite Delivery Contract
- SPE2DB24D3014-SPE2DB26FKRTTDelivery Order
The Defense Logistics Agency awarded a firm fixed price delivery order to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets in quantities of 30 units, with a ceiling value of $8,606.93. The delivery order, issued on October 14, 2025, with an ultimate completion date of October 15, 2025, represents a non-competitive award under the company's existing contract vehicle with DLA. The place of performance is located at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen Drug Corp's prime Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. Ondansetron, an antiemetic medication commonly used in medical settings to prevent nausea and vomiting, represents the type of essential pharmaceutical commodity delivered through this contract to support Defense Health Agency operations and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.6k | 10/14/25 |